For Employers | Field Trip Health

THE PROBLEM

Mental illness continues to be a burden to both employers and employees

quote citations

of Canadian employees are currently experiencing a mental health problem.

19.2

days

the average number of workdays missed annually by people with depression.

of disability costs are attributable to mental illness.

Employees with treatment-resistant depression are 14x more likely to make a long-term disability claim

Source: CMHA, 2020; Morneau Shepell, 2020; Valentstein et al.

Switching antidepressants might not be the answer.

Depression relapse rates increase with every antidepressant switch.

Source: STAR*D study

A new solution

Ketamine-enhanced psychotherapy

What is ketamine?

Ketamine is a dissociative anaesthetic that was first approved by the FDA 50 years ago. Used in sub-anaesthetic doses, it has demonstrated strong efficacy and safety in the treatment of psychiatric and substance use disorders.

How does ketamine work to treat depression and other mental illnesses?

Acting as an NMDA receptor antagonist, ketamine induces neuroplasticity and reduces the activity of the Default Mode Network, which is neurologically analogous to the “ego” and, when overactive, can keep the mind stuck in old thinking patterns and harmful behaviours. Ketamine can be safely administered alongside conventional antidepressant medications (i.e. SSRIs, SNRIs).

Our Process

WHAT WE OFFER

We offer a deeply human experience, combining the science of psychedelic medicine with personalized psychotherapy and wellness practices.

FOR employers

Solutions for businesses and employees

Field Trip offers

Free consultation sessions

Tailored treatment programs

Beautiful clinic spaces

Virtual therapy options

Mental wellness tools and education

Custom employee landing pages

Employer and insurer benefits

Care tailored to employee needs

Improved employee well-being

Improved employee productivity

Reduced disability claims

Reduced healthcare costs

“Several studies demonstrate that ketamine reduces depression within six hours, with effects that are equal to or greater than the effects of six weeks of treatment with other antidepressant medications.”

Dr. Tom Insel · Former Director, nimh

our medical professionals

Field Trip's program and clinics have been developed by a team of leading doctors and practitioners

Dr. Michael Verbora

Medical director

Dr. Michael Verbora, M.D., MBA, studied at the Schulich School of Medicine at Western University before working as a leading physician in several Ontario clinics.

Learn more

Dr. Leora Pinhas

Psychiatrist

Dr. Pinhas is Assistant Professor at the Department of Psychiatry at the University of Toronto, which she has been affiliated with for over 20 years.

Learn more

our advisors

Field Trip's board and advisory team consists of some of the world's most respected health industry leaders.

Dieter Weinand

Board Member

Mr. Weinand is the former President, CEO and Chairman of the Board of Bayer Pharmaceuticals, AG and has 30 years of experience in senior executive roles with a number of pharmaceutical companies, including Sanofi, Otzuka and Pfizer.

Learn more

Helen Boudreau

Board Member

Ms. Boudreau joins the Company’s Board of Directors after serving as COO for the Bill & Melinda Gates Medical Research Institute. Prior to that role, Ms. Boudreau served as CFO for biotech companies Proteostasis Therapeutics and FORMA Therapeutics.

Learn more

Dr. Michael Ehlers

Advisor

Currently CEO of Limelight Bio and Chief Scientific Officer of Apple Tree Partners, Dr. Ehlers was previously Executive Vice President and Head of Research & Development at Biogen, one of the world’s oldest and largest biopharmaceutical companies.

Learn more

OUR LOCATIONs